Kivizidiale (Timolol, Travoprost)

Timolol reduces the production of aqueous humor by blocking β‑adrenergic receptors in the eye, while travoprost increases the outflow of fluid through the uveoscleral pathway as a prostaglandin analog. Together they provide a synergistic pressure‑lowering effect.

The dosing regimen for Kivizidiale is determined by the prescribing ophthalmologist based on the individual patient's condition, response, and tolerance. Patients should follow the specific instructions provided by their healthcare professional.

Safety of Kivizidiale in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified clinician.

To order Kivizidiale, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, the timolol‑travoprost combination offers dual mechanisms—decreased fluid production and increased outflow—resulting in greater intra‑ocular pressure reduction. This can be advantageous over monotherapy when target pressure is not achieved with a single drug.

Store Kivizidiale at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from light and moisture, and ensure the cap is tightly closed to maintain sterility.

Kivizidiale is applied as an eye drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac, avoiding contact between the tip and the eye.

Serious risks include severe allergic reactions, significant eyelid swelling, persistent eye pain, sudden vision loss, and systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm, especially in patients with pre‑existing cardiovascular or respiratory conditions.

Kivizidiale should be avoided in patients with known hypersensitivity to timolol, travoprost, or any excipients, as well as those with severe asthma, chronic obstructive pulmonary disease, sinus bradycardia, second‑ or third‑degree heart block, or uncontrolled heart failure unless specifically directed by a physician.